title: [Cooperative Cardiovascular Disease Research Network (RECAVA)].
abstract: Today, cardiovascular disease is the principal cause of death and hospitalization in Spain, and accounts for an annual healthcare budget of more than 4000 million euros. Consequently, early diagnosis, effective prevention, and the optimum treatment of cardiovascular disease present a significant social and healthcare challenge for the country. In this context, combining all available resources to increase the efficacy and healthcare benefits of scientific research is a priority. This rationale prompted the establishment of the Spanish Cooperative Cardiovascular Disease Research Network, or RECAVA (Red Temática de Investigación Cooperativa en Enfermedades Cardiovasculares), 5 years ago. Since its foundation, RECAVA's activities have focused on achieving four objectives: a) to facilitate contacts between basic, clinical and epidemiological researchers; b) to promote the shared use of advanced technological facilities; c) to apply research results to clinical practice, and d) to train a new generation of translational cardiovascular researchers in Spain. At present, RECAVA consists of 41 research groups and seven shared technological facilities. RECAVA's research strategy is based on a scientific design matrix centered on the most important cardiovascular processes. The level of RECAVA's research activity is reflected in the fact that 28 co-authored articles were published in international journals during the first six months of 2007, with each involving contributions from at least two groups in the network. Finally, RECAVA also participates in the work of the Spanish National Center for Cardiovascular Research, or CNIC (Centro Nacional de Investigación Cardiovascular), and some established Biomedical Research Network Centers, or CIBER (Centros de Investigación Biomédica en RED), with the aim of consolidating the development of a dynamic multidisciplinary research framework that is capable of meeting the growing challenge that cardiovascular disease will present in the future.
authors.forename: David
authors.initials: D
authors.lastname: García-Dorado
authors.forename: Alfonso
authors.initials: A
authors.lastname: Castro-Beiras
authors.forename: Javier
authors.initials: J
authors.lastname: Díez
authors.forename: Rafael
authors.initials: R
authors.lastname: Gabriel
authors.forename: Juan R
authors.initials: JR
authors.lastname: Gimeno-Blanes
authors.forename: Manuel
authors.initials: M
authors.lastname: Ortiz de Landázuri
authors.forename: Pedro L
authors.initials: PL
authors.lastname: Sánchez
authors.forename: Francisco
authors.initials: F
authors.lastname: Fernández-Avilés
mesh_terms: D035843:Biomedical Research / Q000458:organization & administration*; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D013030:Spain